Quick Answer
Seres Therapeutics, Inc. reported Operating Income Loss of -$93.97 million for the year ending 2025.
- Seres Therapeutics, Inc. showed an increase of +22.5% in Operating Income Loss from 2024 to 2025.
- This data is from Seres Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$1.67 million | Q2 2014: -$2.62 million | Q3 2014: -$3.58 million | Q4 2014: -$7.21 million | Q1 2015: -$8.17 million | Q2 2015: -$12.34 million | Q3 2015: -$14.56 million | Q4 2015: -$19.79 million | Q1 2016: -$19.92 million | Q2 2016: -$28.14 million | Q3 2016: -$19.10 million | Q4 2016: -$25.69 million | Q1 2017: -$25.89 million | Q2 2017: -$28.42 million | Q3 2017: -$7.31 million | Q4 2017: -$29.78 million | Q1 2018: -$28.27 million | Q2 2018: -$28.14 million | Q3 2018: -$22.21 million | Q4 2018: -$21.67 million | Q1 2019: -$24.55 million | Q2 2019: -$10.95 million | Q3 2019: -$17.18 million | Q4 2019: -$19.19 million | Q1 2020: -$19.69 million | Q2 2020: -$20.55 million | Q3 2020: -$30.00 million | Q1 2021: -$35.33 million | Q2 2021: -$48.14 million | Q3 2021: $68.41 million | Q1 2022: -$55.75 million | Q2 2022: -$63.33 million | Q3 2022: -$59.11 million | Q1 2023: -$70.57 million | Q2 2023: $49.52 million | Q3 2023: -$44.59 million | Q1 2024: -$34.44 million | Q2 2024: -$28.87 million | Q3 2024: -$29.17 million | Q1 2025: -$27.24 million | Q2 2025: -$24.88 million | Q3 2025: -$22.48 million.
- Over the full 13 years of available data (2013 to 2025), Seres Therapeutics, Inc.'s Operating Income Loss has declined by 1,452.7%.
- Historical annual values: Fiscal year 2025: -$93.97 million | Fiscal year 2024: -$121.32 million | Fiscal year 2023: -$195.10 million | Fiscal year 2022: -$179.91 million | Fiscal year 2021: -$64.49 million | Fiscal year 2020: -$88.13 million | Fiscal year 2019: -$71.88 million | Fiscal year 2018: -$100.28 million | Fiscal year 2017: -$91.40 million | Fiscal year 2016: -$92.84 million | Fiscal year 2015: -$54.86 million | Fiscal year 2014: -$15.08 million | Fiscal year 2013: -$6.05 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: